Cohesion Technologies
This article was originally published in The Gray Sheet
Executive Summary
William Mavity is named president and CEO, effective Oct. 1. Mavity, 51, formerly served as president and CEO of InnerDyne, which was acquired by Tyco's U.S. Surgical business a year ago (1"The Gray Sheet" Oct. 9, 2000, p. 14). The exec will take over from outgoing David Foster, CEO, and Frank DeLustro, president and chief operating officer, as part of a planned transition to focus on biosurgical product commercialization efforts with "a more seasoned executive," the firm explains. Palo Alto, California-based Cohesion is awaiting a rescheduling of an FDA panel review of its CoSeal surgical sealant following a Sept. 11 cancellation (2"The Gray Sheet" Sept. 17, 2001, p. 7)
You may also be interested in...
Timely Rescheduling Of CoSeal Panel Review Expected By Product Sponsor
Cohesion Technologies says it anticipates an "expeditious" reconvening of FDA's Circulatory System Devices Panel, which had planned to review the firm's CoSeal surgical sealant product on Sept. 11.
Tyco Takes Steps To Add InnerDyne Surgical Access Line Via $180 Mil. Bid
Tyco International's purchase of InnerDyne for $180 mil. would give the company access to the Sunnyvale, Calif. firm's Step line of minimally invasive access products for laparoscopic surgery.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.